Drug Search Results
More Filters [+]

FEDAA-1106

Alternative Names: fedaa-1106, fedaa1106, fedaa 1106
Latest Update: 2015-01-08
Latest Update Note: Clinical Trial Update

Product Description

for investigation in patients with Multiple Sclerosis  (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01031199)

Mechanisms of Action: BZD Agonist

Novel Mechanism: Yes

Modality: N/A

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for FEDAA-1106

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Alzheimer Disease|Multiple Sclerosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT01035164

P1

Completed

Alzheimer Disease

2010-01-01

NCT01031199

P1

Completed

Multiple Sclerosis

2009-12-01

Recent News Events

Date

Type

Title